https://biotechmorning.com/news/fda-mixed-signals-moderna-mrna-flu-vaccine Biotech Morning en 2026-06-17T14:25:40.176Z The FDA Can't Decide How It Feels About Moderna's Flu Shot https://biotechmorning.com/news/fda-gene-therapy-cheat-code-prior-knowledge Biotech Morning en 2026-06-17T14:24:47.099Z FDA Just Handed Gene Therapy Developers a Cheat Code https://biotechmorning.com/news/medicare-glp1-obesity-coverage-hard-to-undo Biotech Morning en 2026-06-17T14:23:51.849Z Medicare's New Weight-Loss Drug Benefit Has a Built-In Self-Destruct Shield https://biotechmorning.com/news/biontech-curevac-mRNA-acquisition Biotech Morning en 2026-06-17T14:22:55.977Z BioNTech Just Bought Its Biggest Rival for the Price of a Settlement https://biotechmorning.com/news/fda-reversal-uniqure-huntington-gene-therapy Biotech Morning en 2026-06-17T14:22:05.954Z The FDA Said No to This Gene Therapy. Then It Said Yes. Then No. Then… https://biotechmorning.com/news/altaris-simulations-plus-375m-acquisition Biotech Morning en 2026-06-17T14:21:07.162Z Pharma's Favorite Crystal Ball Just Got Bought by Private Equity https://biotechmorning.com/news/failed-trial-ai-goldmine-verge-labs Biotech Morning en 2026-06-17T14:20:12.864Z The Biotech That Turned a Failed Trial Into an AI Goldmine https://biotechmorning.com/news/incyte-vega-therapeutics-von-willebrand-acquisition Biotech Morning en 2026-06-17T14:19:20.038Z Incyte Just Spent $1.25 Billion on a Disease Most People Haven't Heard Of https://biotechmorning.com/news/novo-nordisk-812m-deep-apple-non-incretin-obesity Biotech Morning en 2026-06-17T14:18:27.420Z Novo Nordisk Just Bet $812M That Obesity's Future Isn't GLP-1 https://biotechmorning.com/news/edgewise-hcm-drug-phase-2-data-competition Biotech Morning en 2026-06-17T14:17:30.781Z The Heart Drug That Wants to Beat BMS and Cytokinetics at Their Own Game https://biotechmorning.com/news/colorado-fda-canada-drug-importation Biotech Morning en 2026-06-16T14:22:48.550Z Colorado Just Got Permission to Buy Its Drugs From Canada https://biotechmorning.com/news/neumora-navacaprant-depression-phase-3-failure Biotech Morning en 2026-06-16T14:22:04.841Z Neumora's Depression Drug Went 0-for-3. Now It's a Penny Stock. https://biotechmorning.com/news/intellia-crispr-hae-one-shot-cure Biotech Morning en 2026-06-16T14:21:08.719Z One Shot to Silence a Disease Forever https://biotechmorning.com/news/europe-clinical-trial-registry-transparency-problem Biotech Morning en 2026-06-16T14:20:13.701Z Europe's Clinical Trial Registry Has a Transparency Problem Nobody's Fixing https://biotechmorning.com/news/spyre-spy002-phase-2-ulcerative-colitis-results Biotech Morning en 2026-06-16T14:19:17.582Z Spyre Just Dropped the Best Report Card in UC's Hottest Drug Class https://biotechmorning.com/news/adaptive-biotechnologies-splitting-diagnostics-drug-discovery Biotech Morning en 2026-06-16T14:18:24.118Z Adaptive Biotech Is Breaking Up With Itself https://biotechmorning.com/news/medicare-subcutaneous-keytruda-opdivo-pricing-loophole Biotech Morning en 2026-06-16T14:17:28.995Z The Escape Hatch That Medicare Wants to Slam Shut https://biotechmorning.com/news/chiesi-kalvista-oral-hae-treatment-acquisition Biotech Morning en 2026-06-16T14:16:36.696Z The $1.9 Billion Pill That Replaced a Needle https://biotechmorning.com/news/ucb-candid-therapeutics-2-billion-acquisition-3 Biotech Morning en 2026-06-16T14:15:37.432Z UCB Just Bet $2 Billion on a Cancer Drug That Might Cure Autoimmune Disease